- Stocks
- Pharma & Healthcare
- Bal Pharma
Bal Pharma share price
NSE: BALPHARMAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Bal Pharma at a glance
Bal Pharma (NSE: BALPHARMA) closed at ₹109.58 on 30 Sep 2026. With a market capitalisation of ₹174 Cr, it ranks 2351st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 27.7× trailing earnings, against a return on equity of 7.7% in FY26. Over the past year the share price has risen 28.9%. Its 52-week range is ₹60.00 (30 Mar 2026) to ₹124.60 (10 Sep 2026); the last close is 12.1% below the high. Promoters held 50.86% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹174 CrRank 2351 on NSE
- P/E (trailing)
- 27.7×
- Price to book
- 1.16×FY26
- ROE
- 7.7%FY26
- ROCE
- 18.0%FY26
- Debt to equity
- 1.94FY26
- Net profit margin
- 2.0%FY26
- Book value / share
- ₹51.65FY26
- 52-week high
- ₹124.6010 Sep 2026
- 52-week low
- ₹60.0030 Mar 2026
- 1-year return
- +28.9%
- RSI (14-day)
- 60.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −2.16% | +1.4% | +28.9% | +37.8% | +28.9% |
Bal Pharma financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹251 Cr | ₹281 Cr | ₹304 Cr | ₹339 Cr | ₹303 Cr | — |
| Operating profit | ₹4 Cr | ₹9 Cr | ₹5 Cr | ₹9 Cr | ₹5 Cr | — |
| Net profit | ₹5 Cr | ₹6 Cr | ₹3 Cr | ₹7 Cr | ₹7 Cr | — |
| EPS (₹) | ₹3.00 | ₹4.00 | ₹2.00 | ₹5.00 | ₹5.00 | — |
| Cash from operations | ₹22 Cr | ₹28 Cr | −₹2 Cr | ₹23 Cr | ₹20 Cr | — |
| Total debt | ₹24 Cr | ₹27 Cr | ₹31 Cr | ₹36 Cr | ₹31 Cr | ₹32 Cr |
| Shareholders' equity | ₹54 Cr | ₹59 Cr | ₹64 Cr | ₹69 Cr | ₹77 Cr | ₹82 Cr |
Bal Pharma shareholding pattern
| Holder | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 50.86% | 50.86% | 50.86% | 50.86% |
| Foreign institutions | 0.22% | 0.14% | 0.14% | 0.15% |
| Non-institutions | 48.92% | 49.01% | 49.01% | 48.99% |
Bal Pharma vs peers
The listed Pharma & Healthcare companies nearest to Bal Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ANLAccretion Nutra | — | — | — | ₹184 Cr | — | — |
| EARKARTEarkart | — | — | — | ₹182 Cr | — | — |
| NOVELIXNovelix Pharma | — | — | — | ₹181 Cr | — | — |
| BALPHARMABal Pharma | ₹109.58 | −2.16% | +28.9% | ₹174 Cr | 27.7 | — |
| MEDICOMedico Remedies | ₹20.71 | −0.43% | −57.5% | ₹172 Cr | 13.1 | — |
| MADHAVBAUGVaidya Sane Ayu | ₹161.10 | −4.11% | −43.1% | ₹169 Cr | — | — |
| TAKETake Solutions | ₹11.23 | −1.23% | −36.8% | ₹166 Cr | 38.7 | — |
Ask anything about Bal Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against BALPHARMA's own history. Try: “Why has BALPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on BALPHARMA over five years” · “Compare BALPHARMA with ANL on margins and valuation”
Frequently asked questions about Bal Pharma
What is the share price of Bal Pharma today?
Bal Pharma (NSE: BALPHARMA) last closed at ₹109.58 on 30 Sep 2026. Its 52-week high is ₹124.60 and its 52-week low is ₹60.00.
What is the market cap of Bal Pharma?
Bal Pharma's market capitalisation is ₹174 Cr (₹174 Cr) at the 22 Oct 2026 close, ranking 2351st among the NSE companies Pivot tracks.
What is the P/E ratio of Bal Pharma?
Bal Pharma trades at a trailing P/E of 27.7.
What is the ROE and ROCE of Bal Pharma?
Return on equity was 7.7% in FY26 and return on capital employed was 18.0% in FY26 (consolidated figures).
Is Bal Pharma a debt-free company?
No. Bal Pharma's debt-to-equity ratio was 1.94 in FY26, with total debt of ₹32 Cr.
How has Bal Pharma stock performed over the last year?
Bal Pharma's share price has risen 28.9% over the past year, +37.8% over three months and +28.9% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Bal Pharma?
As of 30 Jun 2026: promoters 50.86%, foreign institutions 0.15%, non-institutions 48.99%.
Who are Bal Pharma's competitors?
The listed Pharma & Healthcare companies closest to Bal Pharma by market cap are Accretion Nutra, Earkart, Novelix Pharma, Medico Remedies, Vaidya Sane Ayu and Take Solutions.
Is Bal Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Bal Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BALPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 30 Sep 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text